Halozyme Therapeutics (Halozyme Therapeutics) Growth Rank : 9 (As of Apr. 27, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Growth Rank?

Halozyme Therapeutics has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Halozyme Therapeutics's Growth Rank

For the Biotechnology subindustry, Halozyme Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Growth Rank falls into.

Halozyme Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Executives

Michael J. Labarre	officer: SVP, Chief Technical Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley	director, officer: President and CEO	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita	director	20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley	director	1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey	officer: SVP, Chief Commerical Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121